Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Theriva Biologics To Present Preclinical Data For Potential Synergy Of VCN-01 And First-Line Pancreatic Cancer Chemotherapy Regimens At American Society For Cell And Gene Therapy 27th Annual Meeting

Author: Benzinga Newsdesk | April 22, 2024 04:37pm

– Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft–

– The observed synergy emphasizes VCN-01's potential in diverse chemotherapy combinations for improved efficacy in the treatment of pancreatic cancer–

Posted In: TOVX